- |||||||||| Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity. (Pubmed Central) - Nov 3, 2023
Metformin hydrochloride and 2 types of bariatric surgical procedures (sleeve gastrectomy and gastric bypass) were considered in sensitivity analysis...Orlistat and liraglutide cost more and were less effective than phentermine-topiramate and semaglutide, respectively...In this economic evaluation of weight loss drugs for adolescents with severe obesity, we found phentermine-topiramate to be a cost-effective treatment at a willingness-to-pay threshold of $100?000 to $150?000/QALY. Further research is needed to determine long-term drug efficacy and how long adolescents continue treatment.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Enrollment change, Trial withdrawal: Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity (clinicaltrials.gov) - Oct 26, 2023
P2, N=0, Withdrawn,
Further research is needed to determine long-term drug efficacy and how long adolescents continue treatment. N=140 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| Symlin (pramlintide) / AstraZeneca, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Treating obesity in type 1 diabetes mellitus - review of efficacy and safety. (Pubmed Central) - Oct 11, 2023
Treatments also have varying adverse effect profiles which may impact T1D treatment. In this review, we aim to summarize study outcomes in people with T1D, including risks and benefits, of on- and off-label weight loss treatments.
- |||||||||| phentermine / Generic mfg.
Journal: The Use of Phentermine for Obesity in Psychiatric Patients With Antipsychotics. (Pubmed Central) - Oct 5, 2023
In this review, we aim to summarize study outcomes in people with T1D, including risks and benefits, of on- and off-label weight loss treatments. Overall, phentermine was effective and tolerable for patients with obesity taking antipsychotic medications, and ACT (predominantly topiramate) augmented the weight-loss effect of phentermine.
- |||||||||| Saxenda (liraglutide 3 mg) / Novo Nordisk
Enrollment open, Trial completion date, Inflammatory cell: Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - Oct 4, 2023
P=N/A, N=24, Recruiting,
Overall, phentermine was effective and tolerable for patients with obesity taking antipsychotic medications, and ACT (predominantly topiramate) augmented the weight-loss effect of phentermine. Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Shedding light on weight loss: A narrative review of medications for treating obesity. (Pubmed Central) - Sep 27, 2023
The benefit-to-risk of medications, comorbidities, and individual responses should guide the treatment decisions. The article provides a comprehensive overview and discussion of several weight loss medications used previously and currently, including their efficacy, mechanisms of action, and side effects.
- |||||||||| Review, Journal: A narrative review of approved and emerging anti-obesity medications. (Pubmed Central) - Sep 15, 2023
The use of AOM increased enormously despite its sometimes-dubious safety and ineffectiveness. The public and medical professionals should be vigilant to the real-world benefits of anti-obesity drugs and their achieved effectiveness with an improved safety profile.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents. (Pubmed Central) - Aug 31, 2023
In this economic evaluation of pharmacotherapy for adolescents with obesity, top-dose phentermine and topiramate as adjunct to lifestyle counseling was estimated to be cost-effective after 5 years. Long-term clinical trials in adolescents are needed to fully evaluate the outcomes of pharmacotherapy, especially into adulthood.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Review, Journal: A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity. (Pubmed Central) - Aug 29, 2023
In 2022, the phentermine/topiramate (PHEN/TPM), once-daily, controlled-release, combination product received FDA approval, for the indication of chronic weight management, in youth with obesity, ages 12 years and older. The objectives of this narrative review are to: (1) Review the mechanism of action of phentermine and topiramate, (2) Summarize the safety and efficacy data of topiramate and phentermine use as both monotherapies and in combination, and (3) Discuss clinical practice guidelines and clinical implications, for the use of these agents in youths with obesity.
- |||||||||| Journal, Real-world evidence, Adherence, Real-world: Real-world primary nonadherence to antiobesity medications. (Pubmed Central) - Aug 18, 2023
Dr Bengtson is employed at Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim has no connection to this study), and during the conduct of this study was employed at Optum.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Imcivree (setmelanotide) / Rhythm Pharma
Review, Journal: Pediatric Obesity: Complications and Current Day Management. (Pubmed Central) - Jul 29, 2023
Metabolic and bariatric surgery may be used for the management of severe obesity in youth; though highly effective, it is limited to specialized centers and has had relatively low pediatric uptake. In this narrative review using pediatric-focused data from original research, reviews, clinical practice guidelines, governmental agencies, and pharmaceutical companies, we review obesity-related metabolic complications in youth and management strategies, including AOM and bariatric surgery.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Renal Damage and Obesity: a Silent Pairing (Pubmed Central) - Jul 14, 2023
Bariatric surgery techniques that are generally divided into restrictive, malabsorptive, and mixed are not free from possible metabolic complications such as anemia, vitamin deficiency, and stones. However, they are able to ensure a good maintenance of weight loss obtained with disappearance or reduction of the incidence and severity of comorbidities related to obesity.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Review, Journal: Current and future pharmacotherapies for obesity in children and adolescents. (Pubmed Central) - Jun 20, 2023
The importance of a comprehensive and chronic care model, including both lifestyle modification and ongoing pharmacotherapy, will be discussed in the context of maximizing long-term health outcomes. Finally, insight will be provided into the emerging pipeline of AOMs (for example, incretin receptor co-agonists and tri-agonists) and how future therapies might fundamentally change the prognosis for youth with obesity.
- |||||||||| Journal: Obesity prevalence and variability in management practices for patients with symptomatic peripheral artery disease. (Pubmed Central) - Jun 19, 2023
In conclusion, obesity is a prevalent modifiable comorbidity in PAD that is hardly addressed during PAD management, with significant variability across practices. As obesity prevalence rates are growing, along with treatment modalities to treat it, especially in those with PAD, building systems to integrate systematic evidence-based weight and dietary management strategies in PAD are essential to close this gap in care.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Mounjaro (tirzepatide) / Eli Lilly
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. (Pubmed Central) - May 17, 2023
Active, not recruiting --> Completed Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion date, Trial primary completion date: Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients (clinicaltrials.gov) - May 16, 2023
P2a, N=40, Recruiting,
Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents. Trial completion date: Sep 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Review, Journal: Obesity and multiple myeloma: emerging mechanisms and perspectives. (Pubmed Central) - May 15, 2023
In terms of the effect of pharmacological management of obesity, orlistat has been shown to alter the proliferation of MM cells, whereas no data exist on glucagon-like peptide-1 receptor agonists, naltrexone/bupropion, or phentermine/topiramate. Bariatric surgery may be associated with a reduction in the incidence of MM, however, further studies are needed.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Biomarker, Enrollment closed: Risk of Metabolic Adaptation After Weight Loss (clinicaltrials.gov) - May 11, 2023
P=N/A, N=60, Active, not recruiting,
Bariatric surgery may be associated with a reduction in the incidence of MM, however, further studies are needed. Recruiting --> Active, not recruiting
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Trial completion date: EMPOWER-T2D: EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial (clinicaltrials.gov) - Apr 11, 2023
P4, N=69, Active, not recruiting,
Liraglutide or phentermine/topiramate treatment significantly ameliorated liver steatosis and inflammation, but either treatment showed minimal effect on fibrosis improvement. Trial completion date: Mar 2023 --> Jun 2023
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
UTILIZATION OF ANTI-OBESITY MEDICATIONS AFTER BARIATRIC SURGERY: ANALYSIS OF A LARGE NATIONAL DATABASE (W190b - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_5422;
Conclusion : AOMs are underutilized following bariatric surgery. It is pertinent to recognize that, while bariatric surgery is often pursued after failed attempts at medical weight loss, obesity is a chronic relapsing disease and AOMs should continue to be considered following surgery and may offer more successful and sustainable weight loss when used in conjunction.
- |||||||||| PHARMACOGENETIC INTERACTIONS OF MEDICATIONS ADMINSTERED FOR WEIGHT LOSS IN ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (W190b - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_5421;
It is pertinent to recognize that, while bariatric surgery is often pursued after failed attempts at medical weight loss, obesity is a chronic relapsing disease and AOMs should continue to be considered following surgery and may offer more successful and sustainable weight loss when used in conjunction. Aim: To analyze the potential role of genetic variations on the weight loss effect in adults of the US Food and Drug Administration
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
PREVIOUS ANTI-OBESITY MEDICATION INFLUENCES THE WEIGHT LOSS OUTCOMES OF SEMAGLUTIDE TREATMENT FOR OBESITY (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_4568;
The secondary outcome included comparing TBWL% in patients who were previously on GLP-1 agonists (i.e., liraglutide) compared to patients on medications other than GLP-1 agonists (i.e., phentermine/topiramate ER, phentermine, naltrexone/bupropion SR, and orlistat). In our study, the use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes in comparison to AOM-na
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
EFFECTIVENESS AND SAFETY OF WEIGHT LOSS MEDICAL THERAPY IN CROHN'S DISEASE (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_4295;
It is difficult to attribute causality of disease flares to weight loss pharmacotherapy, and the frequency of flares seen here is likely similar to that which is expected annually in the CD population. Overall, given the rising prevalence of obesity in CD patients, the efficacy and safety of weight loss pharmacotherapy deserves further study.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
PREDICTORS OF EXCESS WEIGHT LOSS AFTER ENDOSCOPIC BARIATRIC THERAPY (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_2839;
Baseline weight and degree of hepatic steatosis each negatively predict EWL at six months in patients after IGB or ESG. These patient factors can help inform probable outcomes for individuals with obesity and guide pre-procedural counseling.
- |||||||||| Belviq (lorcaserin) / Eisai, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Xenical (orlistat) / Roche, GSK
Overview of Recent Systematic Literature Reviews on Anti-Obesity Medications in Adults () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1450;
Recent SLRs reflect a range of AOMs and highlight the need for efficacious and safe drug treatment for long-term weight loss to address the substantial burden of obesity. Subsequent SLRs are needed to synthesize evidence on new AOMs once data are published.
- |||||||||| Mounjaro (tirzepatide) / Eli Lilly
Modelling Long-Term Outcomes of Tirzepatide Compared to Lifestyle Modification and Other Anti-Obesity Medications As Treatment for Overweight and Obesity () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_923;
Versus semaglutide, phentermine/topiramate, naltrexone/buproprion, and lifestyle modification (LSM), the model predicted tirzepatide increases life expectancy by 0.06, 0.22, 0.30, and 0.29 years, and increases quality-adjusted life expectancy by 0.17, 0.59, 0.86, and 0.90 QALYs, respectively. Long-term projections using SURMOUNT-1 data in a validated model showed people with overweight and obesity treated with tirzepatide are likely to have longer life expectancy, experience improved quality-of-life, and decreased incidence of obesity-related complications.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Cost-Effectiveness of Long-Term Medication Therapy for Obesity Management () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_523;
The availability of medications, including semaglutide, liraglutide, phentermine/topiramate, and bupropion/naltrexone, provide more options for chronic obesity management. Long-term medication therapy to manage obesity may provide individuals with opportunities for sustained weight loss; however, semaglutide and liraglutide would generally require discounted prices to become a cost-effective life-long obesity management strategy.
- |||||||||| Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion date: Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity (clinicaltrials.gov) - Feb 14, 2023
P2, N=143, Recruiting,
Long-term medication therapy to manage obesity may provide individuals with opportunities for sustained weight loss; however, semaglutide and liraglutide would generally require discounted prices to become a cost-effective life-long obesity management strategy. Trial completion date: Jun 2027 --> Jun 2026
- |||||||||| Review, Journal: Pharmacological Support for the Treatment of Obesity-Present and Future. (Pubmed Central) - Feb 12, 2023
The drugs whose weight-reducing effect is used in the course of the pharmacotherapy of other diseases (e.g., glucose-sodium cotransporter inhibitors, exenatide) are also worth mentioning...These trends also include an assessment of the usefulness of the weight-reducing properties of the drugs previously used for other diseases. The presented paper is an overview of the studies related to both drugs currently used in the pharmacotherapy of obesity and those undergoing clinical trials, taking into account the individual approach to the patient.
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Saxenda (liraglutide 3 mg) / Novo Nordisk
Journal: In brief: Semaglutide (Wegovy) for weight loss in children. (Pubmed Central) - Feb 9, 2023
The presented paper is an overview of the studies related to both drugs currently used in the pharmacotherapy of obesity and those undergoing clinical trials, taking into account the individual approach to the patient. No abstract available
- |||||||||| Contrave (naltrexone/bupropion) / Currax, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen, Saxenda (liraglutide 3 mg) / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Individualized Obesity Pharmacotherapy (clinicaltrials.gov) - Feb 3, 2023
P3, N=200, Completed,
program could yield long-term cost savings for the Veterans Affairs network and meaningful clinical improvements for Veterans with obesity. Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> May 2022 | Trial primary completion date: Jul 2023 --> May 2022
|
